Australia markets closed

Cytosorbents Corporation (CTSO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.9600+0.0301 (+3.24%)
As of 02:41PM EDT. Market open.

Cytosorbents Corporation

305 College Road East
Princeton, NJ 08540
United States
732 329 8885
https://www.cytosorbents.com

Sector(s)Healthcare
IndustryMedical Devices
Full-time employees186

Key executives

NameTitlePayExercisedYear born
Dr. Phillip P. Chan M.D., Ph.D.CEO & Director541.93kN/A1970
Mr. Vincent J. Capponi M.S.President & COO452.62kN/A1958
Ms. Kathleen P. Bloch CPA, M.B.A.Chief Financial Officer395.43kN/A1955
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.Chief Medical Officer463.15kN/A1968
Ms. Terri Anne Powers M.B.A.Vice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Dr. Christian Steiner M.D.Executive Vice President of Sales & MarketingN/AN/AN/A
Mr. Christopher Cramer M.B.A., M.S.Senior Vice President of Business DevelopmentN/AN/AN/A
Dr. Irina B. Kulinets Ph.D.Senior Vice President of Global Regulatory AffairsN/AN/A1955
Jodi HooverExecutiveN/AN/AN/A
Dr. Robert H. Bartlett M.D.Co-Chairman of Cardiac Surgery Advisory Board & Consultant54kN/A1939
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Corporate governance

Cytosorbents Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.